Tagged with AZ

AstraZeneca Russia You have said that AstraZeneca intends to be “in Russia for Russia” and the company has recently announced a large-scale investment in this country, financing a $150Mn domestic facility in Kaluga. What are the implications of this project for AstraZeneca and why was it important for you to invest here?…

AstraZeneca Hungary The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate of threat to MNCs in Hungary? I would say that it has become an extremely difficult environment to operate in. There is a myth that…

AstraZeneca Serbia As the 7th largest pharma MNC worldwide, AstraZeneca is a company that needs no introduction. However, our readers would love to hear more about your operations here in Serbia… Therefore, can you please first provide them with an idea of the key milestones for the company in Serbia, since you…

AstraZeneca UK AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market conditions in the US. In this context, how has the company been performing in its home market and what will be driving your growth in the UK? Our financial results are in…

AstraZeneca France You’ve been at the head of AstraZeneca France for 7 years through during which time there has been a lot of M&A activity in the industry as well as a rising generics market in France and increased regulations for market authorization. How has the business changed for AstraZeneca in this…

AstraZeneca South Korea You have recently taken over the position as head of AstraZeneca in South Korea, after several years working in China. What view did you have of the Korean pharmaceutical sector from a Chinese perspective? My exposure to Korea while in China was much more on the drug discovery and development…

Brazil   With its huge market of 186 million people; its current position as the largest pharma market in Latin America, with strong growth projected; the influx of foreign and local investment into its pharma market; its reputation for conducting high-quality clinical research; and its incredible biological diversity, Brazil seems poised…